A fail­ure in breast can­cer and now a de­lay for Po­livy? Roche can't catch a break

De­spite a sales boost last quar­ter, CEO Sev­erin Schwan not­ed sev­er­al set­backs in a pre­sen­ta­tion for in­vestors on Mon­day, in­clud­ing a de­lay in the phar­ma gi­ant’s mis­sion to bring its dif­fuse large B-cell lym­phoma (DL­B­CL) drug Po­livy to the first line.

Eight months af­ter teas­ing some pos­i­tive topline re­sults in pre­vi­ous­ly un­treat­ed pa­tients, Roche has yet to file for an ap­proval be­cause the FDA has re­quest­ed to see more da­ta on pro­gres­sion-free sur­vival, ac­cord­ing to Bill An­der­son, CEO of Roche Phar­ma­ceu­ti­cals.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER